136 related articles for article (PubMed ID: 10898320)
1. Decorin and actin expression and distribution in patients with chronic hepatitis C following interferon-alfa-2b treatment.
Jármay K; Gallai M; Karácsony G; Ozsvár Z; Schaff Z; Lonovics J; Kovalszky I
J Hepatol; 2000 Jun; 32(6):993-1002. PubMed ID: 10898320
[TBL] [Abstract][Full Text] [Related]
2. Hepatic alpha-smooth muscle actin expression in hepatitis C patients before and after interferon therapy.
Khan MA; Poulos JE; Brunt EM; Li L; Solomon H; Britton RS; Bacon BR; Di Bisceglie AM
Hepatogastroenterology; 2001; 48(37):212-5. PubMed ID: 11268968
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy.
Sakaida I; Nagatomi A; Hironaka K; Uchida K; Okita K
Am J Gastroenterol; 1999 Feb; 94(2):489-96. PubMed ID: 10022652
[TBL] [Abstract][Full Text] [Related]
4. Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy.
Guido M; Rugge M; Chemello L; Leandro G; Fattovich G; Giustina G; Cassaro M; Alberti A
J Hepatol; 1996 Mar; 24(3):301-7. PubMed ID: 8778196
[TBL] [Abstract][Full Text] [Related]
5. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
[TBL] [Abstract][Full Text] [Related]
6. Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin.
Nasti G; Di Gennaro G; Tavio M; Cadorin L; Tedeschi RM; Talamini R; Carbone A; Tirelli U
AIDS; 2001 Sep; 15(14):1783-7. PubMed ID: 11579239
[TBL] [Abstract][Full Text] [Related]
7. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
McHutchison JG; Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi VK; Goodman ZD; Ling MH; Cort S; Albrecht JK
N Engl J Med; 1998 Nov; 339(21):1485-92. PubMed ID: 9819446
[TBL] [Abstract][Full Text] [Related]
8. Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
de Lédinghen V; Trimoulet P; Winnock M; Foucher J; Bourlière M; Desmorat H; Canva V; Capron D; Lévy S; Mion F; Mannant PR; Chêne G; Fleury H; Couzigou P; Bernard PH;
J Hepatol; 2002 May; 36(5):672-80. PubMed ID: 11983451
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
Lindsay KL; Trepo C; Heintges T; Shiffman ML; Gordon SC; Hoefs JC; Schiff ER; Goodman ZD; Laughlin M; Yao R; Albrecht JK;
Hepatology; 2001 Aug; 34(2):395-403. PubMed ID: 11481625
[TBL] [Abstract][Full Text] [Related]
10. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia.
Shiffman ML; Hofmann CM; Contos MJ; Luketic VA; Sanyal AJ; Sterling RK; Ferreira-Gonzalez A; Mills AS; Garret C
Gastroenterology; 1999 Nov; 117(5):1164-72. PubMed ID: 10535880
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathologic observations on chronic hepatitis C therapy with interferon-alpha].
Jármay K; Lonovics J; Schaff Z
Orv Hetil; 2003 Jul; 144(27):1325-30. PubMed ID: 12908145
[TBL] [Abstract][Full Text] [Related]
12. Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation.
Carpino G; Morini S; Ginanni Corradini S; Franchitto A; Merli M; Siciliano M; Gentili F; Onetti Muda A; Berloco P; Rossi M; Attili AF; Gaudio E
Dig Liver Dis; 2005 May; 37(5):349-56. PubMed ID: 15843085
[TBL] [Abstract][Full Text] [Related]
13. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
[TBL] [Abstract][Full Text] [Related]
14. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
15. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
16. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
González-Peralta RP; Kelly DA; Haber B; Molleston J; Murray KF; Jonas MM; Shelton M; Mieli-Vergani G; Lurie Y; Martin S; Lang T; Baczkowski A; Geffner M; Gupta S; Laughlin M;
Hepatology; 2005 Nov; 42(5):1010-8. PubMed ID: 16250032
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
Alsaran K; Sabry A; Molhem A
Ren Fail; 2013; 35(10):1305-9. PubMed ID: 24059964
[TBL] [Abstract][Full Text] [Related]
18. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C.
Kraus MR; Schäfer A; Csef H; Scheurlen M
World J Gastroenterol; 2005 Mar; 11(12):1769-74. PubMed ID: 15793861
[TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.
Bruix J; Poynard T; Colombo M; Schiff E; Burak K; Heathcote EJ; Berg T; Poo JL; Mello CB; Guenther R; Niederau C; Terg R; Bedossa P; Boparai N; Griffel LH; Burroughs M; Brass CA; Albrecht JK;
Gastroenterology; 2011 Jun; 140(7):1990-9. PubMed ID: 21419770
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Manns MP; McHutchison JG; Gordon SC; Rustgi VK; Shiffman M; Reindollar R; Goodman ZD; Koury K; Ling M; Albrecht JK
Lancet; 2001 Sep; 358(9286):958-65. PubMed ID: 11583749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
